Levobupivacaine

CHEMBL1201193 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

288.4 g/mol

LogP

3.4

Phase

4

The S-enantiomer of bupivacaine, a long-acting local anesthetic used for regional anesthesia and pain management. It is considered to have a better safety profile than racemic bupivacaine, particularly regarding cardiac toxicity.

Berat Molekul

288,4000 g/mol

LogP

3,40

TPSA

32,30 Å²

Lipinski RO5

Lulus

Area Terapeutik

Bladder Cancer Endometriosis Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Kidney Disease Stroke Obesity Hypertension Breast Cancer Chronic Pain Colorectal Cancer

Mekanisme Kerja

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C

InChI

InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1

Molecular Formula

C18H28N2O

HBD / HBA

1 / 2

Ikatan yang Dapat Dirotasi

5

Atom Berat

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The S-enantiomer of bupivacaine, a long-acting local anesthetic used for regional anesthesia and pain management. It is considered to have a better safety profile than racemic bupivacaine, particularly regarding cardiac toxicity.

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Yes, Levobupivacaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201193. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 92253. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Levobupivacaine di PillFYI

Struktur

Data Cepat

Rumus: C18H28N2O

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Levobupivacaine

Area Terapeutik

Mekanisme Kerja

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Pertanyaan yang Sering Diajukan

References & Data Sources

Embed This Widget